Primary Ciliary Dyskinesia (PCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Primary ciliary dyskinesia (PCD) is predominantly inherited as an autosomal recessive disorder, leading to recurrent and chronic upper and lower respiratory tract infections. In 40–50% of cases, PCD is associated with mirror-image organ arrangement and other forms of heterotaxy. Currently, pathogenic variants in 45 genes have been identified as causes of PCD. While PCD is typically inherited in an autosomal recessive manner, exceptions include FOXJ1-PCD (autosomal dominant), PIH1D3-PCD, and OFD1-PCD (X-linked). Notably, 20%-30% of individuals with well-characterized PCD lack identifiable pathogenic variants in any associated genes. The progression and severity of lung disease in PCD vary among individuals. More than 75% of full-term neonates with PCD experience “neonatal respiratory distress,” necessitating supplemental oxygen for days to weeks despite term gestation. However, few are diagnosed with PCD at this age. Chronic airway infection becomes evident in early childhood, with most children presenting chronic year-round wet cough, sputum production, and chronic wheezing. Lung function tests typically indicate obstructive lung disease. Sputum cultures commonly reveal oropharyngeal flora, Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus starting in early childhood, followed by an increased prevalence of Pseudomonas aeruginosa (initially smooth, later mucoid). While rare in childhood, non-tuberculous mycobacterial infections occur in more than 10% of adults with PCD. The diagnosis of PCD requires the presence of characteristic clinical phenotypes and either specific ultrastructural ciliary defects identified by transmission electron microscopy or evidence of abnormal ciliary function. Unlike PCD, other disorders associated with chronic sinopulmonary disease and bronchiectasis, such as cystic fibrosis, immunodeficiency (e.g., immunoglobulin G (IgG) subclass deficiency), allergic rhinitis, gastroesophageal reflux disease, and Wegener’s granulomatosis (upper- and lower-airway disease), are not associated with situs abnormalities. Currently, there are no specific therapies that can correct ciliary dysfunction in PCD. The treatments described are empiric and aimed at managing the consequences of dysfunctional cilia and sperm flagella. Limited evidence supports the use of specific therapeutic modalities for PCD. Symptomatic treatments include antibiotics to prevent infection and nasal irrigation. Surgical interventions, such as endoscopic sinus surgery, can improve sinus drainage in patients with recurrent infections. Pulmonary therapies, similar to those used in cystic fibrosis, are often employed to reduce pulmonary diseases.

Thelansis’s “Primary Ciliary Dyskinesia (PCD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Ciliary Dyskinesia (PCD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Primary Ciliary Dyskinesia (PCD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Primary Ciliary Dyskinesia (PCD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Primary Ciliary Dyskinesia (PCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033